64Cu-PSMA-BCH: a new radiotracer for delayed PET imaging of prostate cancer.
Teli LiuChen LiuZhongyi ZhangNing ZhangXiaoyi GuoLei XiaJinquan JiangQing XieKun YanSteven P RoweHua ZhuZhi YangPublished in: European journal of nuclear medicine and molecular imaging (2021)
64Cu-PSMA-BCH was PSMA specific and showed high stability in vivo with lower uptake in liver than 64Cu-PSMA-617. Biodistribution in mice and PCa patients showed similar profile compared with other PSMA ligands and it was safe with moderate effective dosimetry. The increased tumor uptake and T/N ratios by delayed imaging may facilitate the detection of small lesions and guiding targeted biopsies.
Keyphrases
- pet imaging
- prostate cancer
- pet ct
- positron emission tomography
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- computed tomography
- high resolution
- prognostic factors
- type diabetes
- radical prostatectomy
- aqueous solution
- high intensity
- skeletal muscle
- cancer therapy
- metal organic framework
- drug delivery
- label free
- high fat diet induced